000144388 001__ 144388
000144388 005__ 20240229112622.0
000144388 0247_ $$2doi$$a10.1038/s41568-019-0169-x
000144388 0247_ $$2pmid$$apmid:31300807
000144388 0247_ $$2ISSN$$a1474-175X
000144388 0247_ $$2ISSN$$a1474-1768
000144388 0247_ $$2altmetric$$aaltmetric:63476386
000144388 037__ $$aDKFZ-2019-01841
000144388 041__ $$aeng
000144388 082__ $$a610
000144388 1001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b0$$eFirst author$$udkfz
000144388 245__ $$aMolecular characteristics and therapeutic vulnerabilities across paediatric solid tumours.
000144388 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2019
000144388 3367_ $$2DRIVER$$aarticle
000144388 3367_ $$2DataCite$$aOutput Types/Journal article
000144388 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1565174017_32550$$xReview Article
000144388 3367_ $$2BibTeX$$aARTICLE
000144388 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144388 3367_ $$00$$2EndNote$$aJournal Article
000144388 520__ $$aThe spectrum of tumours arising in childhood is fundamentally different from that seen in adults, and they are known to be divergent from adult malignancies in terms of cellular origins, epidemiology, genetic complexity, driver mutations and underlying mutational processes. Despite the immense knowledge generated through sequencing efforts and functional characterization of identified (epi-)genetic alterations over the past decade, the clinical implications of this knowledge have so far been limited. Novel preclinical platforms such as the European Innovative Therapies for Children with Cancer-Paediatric Preclinical Proof-of-Concept Platform and the US-based Pediatric Preclinical Testing Consortium are being developed to try to change this by aiming to recapitulate the extensive heterogeneity of paediatric tumours and thereby, hopefully, improve the ability to predict clinical benefit. Numerous studies have also been established worldwide to provide patients with access to real-time molecular profiling and the possibility of more precise mechanism-of-action-based treatments. In addition to tumour-intrinsic findings and mechanisms, ongoing studies are investigating features such as the immune microenvironment of paediatric tumours in comparison with adult cancers - currently of very timely clinical relevance. However, there is an ongoing need for rigorous preclinical biomarker and target validation to feed into the next generation of molecularly stratified clinical trials. This Review aims to provide a comprehensive state-of-the-art overview of the molecular landscape of paediatric solid tumours, including their underlying genomic alterations and interactions with the microenvironment, complemented with our current understanding of potential therapeutic vulnerabilities and how these can be preclinically tested using more accurate predictive methods. Finally, we provide an outlook on the challenges and opportunities associated with translating this overwhelming scientific progress into real clinical benefit.
000144388 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000144388 588__ $$aDataset connected to CrossRef, PubMed,
000144388 7001_ $$00000-0003-2188-0003$$aBanito, Ana$$b1
000144388 7001_ $$00000-0003-0920-7377$$aGrünewald, Thomas G P$$b2
000144388 7001_ $$00000-0003-2036-8817$$aHaber, Michelle$$b3
000144388 7001_ $$0P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aJäger, Natalie$$b4$$udkfz
000144388 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b5$$udkfz
000144388 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b6$$udkfz
000144388 7001_ $$aMolenaar, Jan J$$b7
000144388 7001_ $$aNabbi, Arash$$b8
000144388 7001_ $$aPugh, Trevor J$$b9
000144388 7001_ $$aSchleiermacher, Gudrun$$b10
000144388 7001_ $$aSmith, Malcolm A$$b11
000144388 7001_ $$0P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aWestermann, Frank$$b12$$udkfz
000144388 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b13$$eLast author$$udkfz
000144388 773__ $$0PERI:(DE-600)2060549-3$$a10.1038/s41568-019-0169-x$$gVol. 19, no. 8, p. 420 - 438$$n8$$p420 - 438$$tNature reviews / Cancer Cancer [...]$$v19$$x1474-1768$$y2019
000144388 909CO $$ooai:inrepo02.dkfz.de:144388$$pVDB
000144388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144388 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-2188-0003$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000144388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000144388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000144388 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000144388 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000144388 9141_ $$y2019
000144388 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144388 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144388 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144388 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV CANCER : 2017
000144388 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144388 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144388 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144388 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144388 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144388 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144388 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144388 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144388 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144388 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144388 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000144388 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bNAT REV CANCER : 2017
000144388 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lNachwuchsgruppe Pädiatrische Gliomforschung$$x0
000144388 9201_ $$0I:(DE-He78)B380-20160331$$kB380$$lNWG Weichteilsarkome$$x1
000144388 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x2
000144388 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x3
000144388 9201_ $$0I:(DE-He78)B087-20160331$$kB087$$lNeuroblastom Genomik$$x4
000144388 980__ $$ajournal
000144388 980__ $$aVDB
000144388 980__ $$aI:(DE-He78)B360-20160331
000144388 980__ $$aI:(DE-He78)B380-20160331
000144388 980__ $$aI:(DE-He78)B062-20160331
000144388 980__ $$aI:(DE-He78)B310-20160331
000144388 980__ $$aI:(DE-He78)B087-20160331
000144388 980__ $$aUNRESTRICTED